D-0311-2020 Class II Terminated
FDA drug recall D-0311-2020 was initiated by Novitium Pharma LLC on Oct 25, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Presence of NDMA impurity detected in product. The recall status is terminated (terminated Mar 17, 2021). Affected quantity: 2718 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 20, 2019
- Initiation Date
- Oct 25, 2019
- Termination Date
- Mar 17, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 2718 bottles
Product description
Novitium Pharma Ranitidine Capsules 150 mg 500 capsules Rx Only Manufactured by: Novitium Pharma LLC 70 Lake Drive, East Windsor, New Jersey 08520 NDC 70954-001-40
Reason for recall
CGMP Deviations: Presence of NDMA impurity detected in product.
Distribution pattern
Nationwide
Code information
all lots within expiry.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0311-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026